<DOC>
	<DOCNO>NCT01969565</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability increase dos carfilzomib combination dexamethasone</brief_summary>
	<brief_title>Study Carfilzomib Combination w/Dexamethasone Patients w/Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects must newly diagnose multiple myeloma immunoglobulin G ( IgG ) , immunoglobulin A ( IgA ) , immunoglobulin E ( IgE ) immunoglobulin D ( IgD ) International Myeloma Foundation ( IMF ) 2003 Diagnostic Criteria Subjects must treatment naïve . Patient must previously treat prior systemic therapy treatment multiple myeloma . Prior treatment hypercalcemia spinal cord compression corticosteroid disqualify patient ( dose exceed equivalent 160 mg dexamethasone 2 week period ) . Patients treat local radiotherapy without concomitant exposure steroid , pain control management cord/nerve root compression , eligible . One week must lapse since last date radiotherapy , recommend limited field . Patients require concurrent radiotherapy entry protocol defer radiotherapy complete one week pass since last date therapy . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . All necessary baseline study determine eligibility must obtain within 21 day prior enrollment . Age 18 year time signing Informed Consent . Life expectancy three month . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Karnofsky performance status ≥ 60 . Subject must able adhere study visit schedule protocol requirement . Written inform consent accordance federal , local , institutional guideline . Female subject childbearing potential must negative serum pregnancy test within seven day first dose agree use dual method contraception 3 month follow last dose drug . Post menopausal female ( &gt; 45 year old without menses &gt; 1 year ) surgically sterilize female exempt pregnancy test . Male subject must use effective barrier method contraception study three month follow last dose sexually active female childbearing potential . Subjects must able receive outpatient treatment laboratory monitor institute administers agent . Patient &gt; Grade 2 peripheral neuropathy clinical examination within 14 day enrollment . Renal insufficiency measure calculated creatinine clearance &lt; 15 mL/min CockroftGault formula ) . Subjects evidence mucosal internal bleeding and/or platelet refractory ( i.e. , unable maintain platelet count 50,000 cells/mm3 ) . Subjects absolute neutrophil count ( ANC ) &lt; 1000 cells/mm3 . Growth factor may use meet ANC eligibility criterion . Total bilirubin &gt; 2.0 mg/dL bilirubin ≥ 2 x upper limit normal ( ULN ) . Subjects hemoglobin &lt; 8.0 g/dL ( Transfusion permit ) . Alanine aminotransferase ( ALT ) ( SGPT ) &gt; 2.5 x ULN . Aspartate aminotransferase ( AST ) ≥ 2.5 x ULN . Major surgery within three week start study drug ( Cycle 1 Day 1 ) . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality screen document investigator medically relevant . Clinically relevant active infection require either oral intravenous antibiotic antifungal agent . Serious comorbid medical condition chronic obstructive chronic restrictive pulmonary disease , cirrhosis . Any condition , include laboratory abnormality , opinion Investigator place subject unacceptable risk he/she participate study . Prior malignancy ( within last 3 year ) except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , situ prostate cancer expect survival malignancy le 90 % 5 year . Uncontrolled diabetes mellitus ( Fasting Blood Sugar &gt; 400 despite medical treatment ) . Known history POEMS syndrome ( plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein ( Mprotein ) skin change ) . Known HIV infection . Known active hepatitis B C viral infection . Plasma cell leukemia . Glucocorticoid therapy ( prednisone &gt; 20 mg/day equivalent ) within last three week . Any prior treatment multiple myeloma standard regimen investigative regimen . Subjects treatment relate myelodysplastic syndrome . Subjects require program oral intravenous fluid hydration contraindicate , e.g. , due preexist significant pulmonary , cardiac renal impairment . Subjects know primary amyloidosis . Female subject pregnant breastfeeding . Serious medical psychiatric illness likely interfere participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>